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       ABSTRACT
Background Mast cells are cells filled with cytoplasmic secretory granules and are found
in both the adventitia and the intima of human coronary arteries. The mast cell granules
contain vasoactive substances (notably histamine), proteolytic enzymes, cytokines,
growth factors, and proteoglycans. To exert pathophysiological effects in tissues, mast
cells need to become activated and secrete their granular contents. This work elucidated
with the aid of immunohistochemistry, some of the mechanisms which potentially may
activate mast cells in atherosclerotic human coronary arteries.
Results  We found that adventitial mast cells in atherosclerotic coronary plaques resided
in areas where other inflammatory cells (macrophages and T lymphocytes) were also
present. In these areas the degree of mast cell degranulation was significantly higher than
in the coronary adventitias backing normal intimas. Interestingly, in the adventitia of
atherosclerotic coronary segments, a fraction of the mast cells were found to connect with
sensory nerve fibres which contained neuropeptides capable of stimulating mast cells, i.e.
substance P and calcitonin gene-related peptide. Furthermore, we found strong staining
for iC3b and weaker staining for C5b-9 indicating complement activation in advanced
coronary lesions, especially at the sites of plaque rupture. During complement activation
to C3 and C5 levels, anaphylatoxins C3a and C5a are also generated. Importantly, in the
atherosclerotic coronary arteries, but not in the nonatherosclerotic coronary intimas, the
anaphylatoxin receptors for C3a and C5a  were present. Plaque macrophages expressed
both C3aR and C5aR, whereas plaque T cells and mast cells expressed only C5aR.
Conclusion. In the adventitia, the macrophages and T lymphocytes as well as sensory
nerves may activate mast cells to degranulate. Since many of the adventitial mast cells
were located adjacent to adventitial vasa vasorum and at the border between the
adventitia and the media, the histamine released from the activated mast cells may reach
the media, where it may locally provoke coronary spasm and so contribute to the onset of
myocardial infarction. Furthermore, the presence of the molecular components necessary
for anaphylatoxin-mediated activation of mast cells, and also of other inflammatory cells,
in coronary plaques makes anaphylatoxin receptors potential candidates for the regulation
of inflammation in atherosclerotic human coronary arteries.
10
1. INTRODUCTION
Mast cells originate in the bone marrow as pluripotent stem cells. These multilineage
circulating progenitors migrate into various tissues, notably the various mucosal surfaces
and the skin. In the tissues, the precursors are then converted into mature mast cells, the
hallmark of which is their high content of cytoplasmic granules. The mast cell granules
contain large amounts of vasoactive substances, proteolytic enzymes, cytokines, growth
factors, and proteoglycans. For their acute effects, the mast cells have to be activated to
degranulate and secrete a fraction of their granular contents. The activated mast cells also
start to generate and secrete lipid mediators (leukotrienes and prostaglandins) from
arachidonic acid, and, in addition, proinflammatory cytokines, such as tumor necrosis
factor-α (TNF-α; Kovanen 1995, Kaartinen et al. 1996b).
The presence of mast cells has been demonstrated in human coronary arteries, both in the
inner layer (the intima) and the outer layer (the adventitia) of these arteries. Upon coronary
atherogenesis, blood-derived lipids accumulate in the intima, and coronary plaques develop
(Kaartinen et al. 1994a, Pomerance 1958). In the atherosclerotic coronary plaques, the
numbers of degranulated mast cells are high, especially in the shoulder area of the plaque,
the predilection site for plaque rupture. Importantly, degranulated mast cells are present at
the actual sites of erosion or rupture of human coronary atherosclerotic plaques (Kovanen
et al. 1995). Increased numbers of mast cells have also been found in the adventitia of
human atherosclerotic coronary arteries (Pomerance 1958, Atkinson et al. 1994).
Interestingly, in a patient with variant angina, the number of adventitial mast cells was
highest in the spastic coronary segment (Forman et al. 1985). Thus, activated coronary
mast cells may contribute to acute coronary events by multiple mechanisms, (i) by
degrading the extracellular matrix of plaques, so rendering them susceptible to rupture, and
(ii) by contributing to spasms of atherosclerotic coronary segments with vulnerable
plaques.
The present work attempts to unravel some of the potential activation mechanisms of mast
cells in atherosclerotic human coronary arteries. The approach was to study coronary
samples obtained at autopsy from patients with coronary atherosclerosis by
immunohistochemical methods.
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2. REVIEW OF THE LITERATURE
2.1. Coronary arteries
2.1.1. Normal arterial wall
The arterial wall has three histologically different layers. The layers, from the lumen
outward, are the intima, the media and the adventitia. The intima is separated from the
media by the internal elastic lamina (IEL), which is considered to be part of the media. The
external elastic lamina separates the media from the adventitia (Stehbens 1995).
2.1.1.1. The intima
The intima is composed of the endothelium seated on the specialized extracellular matrix
(ECM), the basement membrane, and smooth muscle cells, which are the main source of
the extracellular matrix of the arterial intima. The media contains two layers. The inner
layer, subjacent to the lumen, is called the proteoglycan layer, because it contains
nonfibrous connective tissue which has proteoglycan as its ground substance. The outer
layer is called the musculoelastic layer because of the abundance of smooth muscle cells
and elastic fibers. These layers may be absent or barely visible in light microscopy in
segments of the arteries with a very thin intima (Stehbens 1995). However, the intima may
have some areas with nonspecific thickening (AHA class I, Stary et al. 1994).
2.1.1.2. The media
The media, the middle layer of the muscular artery, consists of diagonally oriented smooth
muscle cells surrounded by variable amounts of collagen, small elastic fibers and
proteoglycans (mucopolysaccharides). These smooth muscle cells form helices through the
vessel wall. The media of the coronary artery is characterized by units in which several
layers of smooth muscle cells are bounded on each side by fenestrated sheets of elastic
tissue (Stehbens 1995).
2.1.1.3. The adventitia
The adventitia, the outermost layer of the coronary artery, consists principally of
fibroblasts intermixed with smooth muscle cells loosely arranged between bundles of
collagen and surrounded by proteoglycans. The adventitial layer also contains nerve fibers
and vasa vasorum, i.e. the vessels supplying blood to the media and the outer third of the
intima. The adventitia is usually separated from the media by a discontinuous sheet of
elastic tissue, the external elastic lamina (Stehbens 1995).
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2.1.2. Atherosclerotic coronary arterial wall (AHA classification II  VI)
Coronary atherosclerosis is predominantly a disease of the intima. Whereas a healthy
coronary intima measures a fraction of a millimeter in thickness, atherosclerosis results in
intimal thickening of up to two or three millimeters. This follows progressive infiltration
by smooth muscle cells, macrophages, and foam cells lying in an extracellular matrix made
up of collagen, proteoglycans and extracellular lipid. In the presence of atherosclerosis, the
media undergoes fibrous degenerative change, particularly of the inner third. In the earlier
stages of atheroma development, the caliber of the arterial lumen does not change
appreciably as a consequence of compensatory enlargement of the vessel (Stary et al.
1995).
2.1.2.1. The classification of atherosclerotic lesions according to the American
Heart Association (AHA)
In the histological classification of lesions in human coronary arteries, classes I and II are
early lesions, class III lesions intermediate lesions, and classes IV, V, VI, VII and VIII, are
advanced lesions (Figure 1). Early lesions with minimal lipid accumulations occur at a
young age in almost everyone and in many locations of the coronary intima. Progression
beyond the class II morphology requires an additional stimulus, i.e. risk factors for the
development of atherogenesis (Stary et al. 1995). In this study we examined segments of
the left anterior descending coronary artery with lesion classes I-VI.
2.1.2.1.1. Class II lesion (fatty streaks)
The earliest lesions of atherosclerosis are fatty streaks, which are composed histologically
of closely packed lipid-laden foam cells. The vast majority of foam cells are macrophages,
a minimal component being of smooth muscle cell origin. In the coronary arteries class II
lesions occur at the same anatomical sites where atherosclerotic plaques preferentially
develop. These lesions increase the thickness of the intima by less than a millimeter and do
not obstruct coronary blood flow to any degree. Some macrophages without lipid droplets
are found in these lesions. T lymphocytes are less numerous than macrophages (Stary et al.
1994).
2.1.2.1.2. Class III lesion (preatheroma)
Class III lesion is also known as the preatheroma or intermediate lesion between minimal
and advanced intimal lesions. These lesions thicken the intima only slightly more than
class II and do not obstruct blood flow. The extracellular lipid particles accumulate to the
extent that multiple separate, but not sharply defined, pools of this material form among
the layers of smooth muscle cells in intimal thickenings. These accumulations of
extracellular lipid replace the proteoglycans and, by increasing the extracellular matrix,
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drive the smooth muscle cells apart. Some macrophages without lipid deposits and T
lymphocytes are present in the subendothelial space (Stary et al. 1994).
2.1.2.1.3 Class IV lesion (atheroma)
In class IV lesions also called atheroma, the lipid core with a dense extracellular lipid
forms by the increase and confluence of smaller, separated pools that characterize the
preatheroma. The lipid core is in the musculoelastic part of the intima. That part of the
intima called the cap, which lies between the lipid core and the lumen of the artery,
contains macrophages and smooth muscle cells, lymphocytes (Jonasson et al. 1986) and
mast cells (Kaartinen et al. 1994a). These inflammatory cells are also numerous in the core
periphery. Capillaries often border the lipid core, particularly at its lateral margins and on
the side facing the lumen. Class IV lesions may not narrow the arterial lumen much and in
many patients this type of lesion may not be visible in angiography. However, class IV
lesions have the potential to quickly develop symptom-producing fissures, hematoma and
thrombus (Stary et al. 1995).
2.1.2.1.4. Class V lesion (fibroatheroma)
Class V lesions have prominent newly formed fibrous connective tissue. Sometimes the
new fibrous tissue accounts for more of the thickness of the lesion than does the underlying
lipid accumulation. When the prominent connective tissue is part of a lesion with a lipid
core, the lesion is called a fibroatheroma or type Va lesion. In a type Vb lesion, the lipid
core and other parts of the lesion are calcified and the lesion is referred as a calcific
atheroma. Indeed, mineral deposits may replace the accumulated remnants of dead cells
and extracellular lipid, including entire lipid cores. A type V lesion, in which a lipid core is
absent and lipid in general is minimal, may be referred to as a type Vc or fibrotic atheroma.
The fibrotic lesions may be the result of one or more processes, including organization of
thrombi, extension of the fibrous component of an adjacent fibroatheroma, or resorption
(regression) of lipid cores. With all type V lesions, the arteries are narrowed to some
degree, generally more than with type IV. Type V lesions, like type IV lesions, may
develop fissures, hematoma, and thrombus (type VI lesion) (Stary et al. 1995).
2.1.2.1.5. Class VI lesion (complicated lesion)
Class VI characteristically consists of disruption of the lesion surface by fissures, erosions,
or ulcerations, a hematoma or hemorrhage and thrombotic deposits. Thus, type VI lesions
are also called complicated lesions. Mostly, this type of lesion has the underlying
morphology of class IV or V (Stary et al. 1995). However, retrospective analysis of serial
angiograms as well as prospective serial angiographic observations have suggested that, in
nearly two thirds of all patients presenting with acute coronary syndromes, a prior coronary
angiogram performed weeks to months before the acute event had shown the culprit lesion
site to have narrowing of the diameter to less than 70% (Falk et al. 1995, Little et al. 1988).
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Figure 1. Changes in the coronary intima during atherogenesis. Class
Adapted from Stary et al. (1995).
2.1.2.2. Morphological changes in the arterial media and adventitia in
atherosclerotic arteries
As an atherosclerotic plaque develops, the cross-sectional area of the coronary artery
increases in order to preserve the normal lumen size (Glagov et al. 1987, McPherson et al.
1991). In general, plaques with hemorrhage and inflammation, characterized by large lipid
cores, infiltrates of macrophages, and calcific deposits, are much more likely to undergo
plaque expansion than plaques without these features (Clarkson et al. 1994, Burke et al.
2002). Previous studies have also shown that structural changes of the intimomedial
interface with enlargement of the IEL area and medial atrophy are associated with
compensatory enlargement in vulnerable atherosclerotic plaques (Pasterkamp et al. 1998,
Burke et al. 2002). The adventitial inflammation has been shown to be stronger in those
segments that have a larger lipid area in the intima of the aorta (Moreno et al. 2002).
Moreno and his group also showed that early lesions, such as nonspecific intimal
thickening (class I) and fatty streaks (class II), have preserved the internal elastic lamina
IEL, the normal tunica media with preserved thickness, and a very low incidence of
adventitial inflammation. The preatheroma (class III) has a mild incidence of IEL rupture
(8%) with increased medial fibrosis (20%) and decreased medial thickness. Adventitial
inflammation is usually very low in class III lesions. In contrast, IEL rupture, medial
changes, and adventitial inflammation are present in advanced plaques (class IV to Vc) and
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are highest in disrupted (class VI) plaques. Extensive areas of IEL rupture are present in
18% to 27% of advanced plaques and in 85% of disrupted plaques. In addition, rupture of
the IEL predictes fibrous cap disruption and is associated with an increased incidence of
medial inflammation, fibrosis, and atrophy (Moreno et al. 2002).
2.2. Mast cells
2.2.1. Introduction
Mast cells were first described by Paul Ehrlich, who gave them their name (Mastzellen =
well-fed cells). The well-fed cells refers to the characteristic cytoplasmic granules in the
mast cells (Ehrlich P 1879). Some years later, Elie Metchnikoff suggested that mast cells
on account of their phagocytotic capacity, might contribute to host defense (Metchnikoff
1892). Mast cells can indeed phagocytose (Kovanen 1993, Malaviya et al. 1996), although
this ability is attributed mainly to macrophages and neutrophils. The main functions of
mast cells, however, are probably to regulate vascular functions at the initiation of an
inflammatory response and to activate other cells. Mast cells also initiate immediate
hypersensitivity reactions, modulate allergic inflammation, and participate in the immune
response to parasitic infections.
2.2.2. Mast cell morphology
Mast cells are round or elongated in shape, with characteristic, metachromatically staining
cytoplasmic granules (Johansson et al. 1994). The surface architecture of mast cells is
composed of narrow, elongated folds. The nucleus is ovoid and non segmented and in the
cytoplasm there are the usual cell organelles, such as the Golgi apparatus, mitochondria,
and some endoplasmic reticulum. However, the dominant cytoplasmic element is granules.
Mast cells, when stimulated, can exocytose a fraction of their secretory granules in to the
surrounding tissue, a process called degranulation.
2.2.3. Mast cell origin and differentiation
Mast cells are derived from multipotential stem cells in bone marrow. The undifferentiated
precursors are carried by the bloodstream to their final tissues of deposition. These
precursors are also found in bone marrow, blood, and mucosal and connective tissues.
When given appropriate stimulation the precursors proliferate and differentiate into mast
cells. (Kitamura et al. 1993). The factor(s) which regulate the maturation of the mast cell
the factor responsible for the local development of mast cells, one strong candidate is the
stem cell factor (SCF). In all the experimental systems studied so far, the development of
mast cells of connective tissue type appears to depend on the presence of SCF (Galli et al.
1995, Li and Krilis 1999). Moreover, of the many cytokines studied in the adult human
system, only SCF promoted the development of mast cells (Valent et al. 1992, Li and Krilis
1999). SCF is also a potent agent for mobilizing the mast cell precursors from the bone
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marrow to the peripheral blood (Okumura et al. 1996) and is also thought to act as a
chemotactic agent to enhance their migration from the circulation into the tissues (Nilsson
et al. 1994a).
2.2.4. Heterogeneity and distribution of mast cells
The modern human mast cell classification was done by Irani et al.. (Irani et al. 1986), who
found that some human mast cells contain both tryptase and chymase (MCTC), whereas
others contain tryptase (MCT) but no measurable chymase in their granules (Irani et al.
1989). Also, a third mast cell type (MCC) containing chymase and carboxypeptidase, but
not tryptase, has also been described (Weidner et Austen 1993). However, it has recently
been suggested that this might represent a dead mast cell in the tissue from which tryptase
has solubilized away meanwhile chymase has remained at the site of cell death (Kivinen et
al. 2003).
The anatomic location of the MCT and MCTC populations is not distinct. For example, in
the human intestinal mucosa the majority of mast cells present are MCT (81%) with only
19% of the total mast cells exhibiting the MCTC phenotype. Conversely, in the human
intestinal submucosa, MCTC are the predominant mast cell phenotype (77%) with only
23% of the total mast cells exhibiting the MCT phenotype in this location. (Irani et al.
1989) Mast cells containing only tryptase are also the predominant mast cells in the lung,
but MCTC are predominant in the skin (Table 1.; Irani et al. 1986 and 1989).
Table 1. Tissue Distribution (%) of Human MCT and MCTC populations
Tissue localization MCT MCTC
Skin 1 99
Lung
Bronchial epithelium 99 1
Bronchial subepithelium 77 23
Alveoli 93 7
Dispersed lung cells 90 10
Small intestine
Mucosa 98 2
Submucosa 13 87
Nasal mucosa
Epithelium 100 0
Subepithelium 60 40
Conjunctiva
Epithelium 100 0
Subepithelium 20 80
MCT = human mast cells containing tryptase
MCTC = human mast cells containing both tryptase and chymase
Mast cells in different anatomic sites, and even in a single site, can exhibit substantial
differences in mediator content, in sensitivity to agents that induce activation and mediator
release, and in their response to pharmacological agents (Irani et al. 1986 and 1989).
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2.2.5. Factors that activate mast cells
The best understood immunological stimulus of mast cells is the so-called "bridging of IgE".
In this system, IgE-sensitized mast cells are activated upon encountering with a specific
antigen (allergen), which is recognized by the antigen-specific IgE molecules bound to the
Fc_RI-receptors on the mast cells (Ishizaka et al. 1984). Apart from activation by means of
Fc_RI, mast cells are also activated by cross-linking of surface FcγRIII molecules with
immunocomplexes (Dombrowicz et al. 1997), or when anaphylotoxins (C3a, C5a) are bound
to their respective receptors expressed on mast cells (Hartmann et al. 1997, Schulman et al.
1988). Moreover, platelet-activating factor (Nilsson et al. 2000), a range of small peptides,
including substance P (Ebertz et al. 1987) and calcitonin gene-related peptide (Church et al.
1989) and b-chemokines, such as macrophage inflammatory protein-1a and monocyte
chemoattractant peptide-1 (Alam et al. 1994) can activate mast cells. In addition, activation
of mast cells may also be provoked by cells of several types, including macrophages, T
lymphocytes, neutrophils, and eosinophils, which secrete mast cell-stimulating factors.
(Sedgwick et al. 1981, Schulman et al. 1985, Liu et al. 1986, Mekori and Metcalfe 1999).
Stem cell factor (SCF) has been found to activate human mast cells directly (Lorentz et al.
2002). By itself, SCF induces only a weak, but significant release of histamine (Ashman et
al. 1999, Nilsson et al. 1994b), and augments the de novo synthesis of prostaglandin D2
(PGD2) (Ashman et al. 1999) and the production of TNF-α from mast cells (Bischoff et al.
1999). Furthermore, SCF is very potent in enhancing the effects of IgE-dependent mast-cell
activation (Ashman et al. 1999, Nilsson et al. 1994b). SCF enhances IgE-dependent release
of preformed mediators such as histamine and also the de novo synthesis of lipid mediators
and cytokines (Ashman et al. 1999, Kinashi et al. 1994, Nilsson et al. 1994b). Interestingly,
SCF does not affect mediator release from mast cells activated with either substance P
(Ashman et al. 1999) or the calcium ionophore (Nilsson et al. 1994b), thereby demonstrating
a specificity in the mechanism of SCF-enhanced mast-cell activation.
Finally, there is an extensive list of the various compounds and activities that can cause
mast cells to degranulate. These include bacteria (Malaviya et al. 2001, Malaviya et al.
2002), free radicals (Kimura et al. 1998), hormones (Nicovani et al. 2002), physical
stresses (Ercan et al. 1999), exercise (O'Sullivan et al. 1998) and pressure (Hara et al.
2002), emotional stress (Spanos et al. 1997), radiation (including solar radiation) (Kronauer
et al. 2001, Hart et al. 2002), toxins (Harari et al. 2000), and viruses (Everard et al. 1995,
Chen et al. 2000), the contrast media used in radiology (Genovese et al. 1996), and various
drugs and chemical compounds (Nosal et al. 1994, Marone et al. 1993, Vassimon et al.
1990, Church et al. 1991).
2.2.6. Mast cell mediators and effects
Mast cells contain, or elaborate on appropriate stimulation, a diverse array of potent
biologically active mediators that can have many different potential effects in
inflammation, tissue remodeling, and organ function at sites of mast cell activation.
(Metcalfe et al. 1997, Bienenstock et al. 1991, Huang et al. 2002, Gordon et al. 1990,
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Metsärinne et al. 2002). Some of these products are stored preformed in the cells
cytoplasmic granules, whereas others are synthesized on appropriate cell activation
(Theoharides 2002).
The secretory granule of the human mast cell contains a crystalline complex of preformed
inflammatory mediators ionically bound to a matrix of proteoglycans. When mast cell
activation occurs, the granules swell and lose their crystalline nature as the mediator
complex becomes solubilized; and the individual mediators are expelled into the local
extracellular environment by a process of compound exocytosis. Moreover, increasing
evidence indicates that some molecules are released from mast cells without degranulation,
a process termed differential release. This was first reported for serotonin. (Theoharides
et al. 1982) Other biogenic amines (Dvorak et al. 1996), arachidonic acid products (Benyon
et al. 1989), and cytokines (Gagari et al. 1997) may also be released differentially.
When mast cells are activated they release a wide range of bioactive mediators (Table 2.),
including biogenic amines such as histamine; proteinases such as tryptase, chymase,
carboxypeptidase, a cathepsin G-like protease (Lutzelschwab et al. 1997), and matrix
metalloproteinases 1-3 and 9 (Johnson et al. 1998, Di Girolamo and Wakefield 2000,
Chancey et al. 2002); lipid mediators, e.g. prostaglandin D2 and leukotriene C4
(Yamaguchi et al. 1999); and cytokines (Mekori and Baram 2002, Yano et al. 1997) and
other growth factors (Bradding and Holgate 1999), e.g. bFGF (Qu et al. 1998), GM-CSF
(Okayama et al. 1998), TGF-β (Pennington et al. 1992), VEGF (Grutzkau et al. 1998),
TNF-α (Gordon et al. 1990), IL-3 (Ishizuka et al. 1999b), IL4, IL-5 (Okayama et al. 1995),
IL-6 (Bradding and Holgate 1999), IL-8 (Aoki et al. 2003), IL-10 (Ishizuka et al. 1999a)
and IL-13 (Jaffe et al. 1996), IL-16 (Rumsaeng et al. 1997). These mediators induce
vasodilation or -contraction (Russell et al. 1994, Rydning et al. 2002, Forman et al. 1985,
Kolodgie et al. 1991, Clejan et al. 2002), angiogenesis (Norrby 1997), vascular
permeability (Kubes et al. 1996, Singh et al. 1999) and smooth muscle contraction (Garrity
et al. 1983, Katada et al. 1999), and contribute to the regulation of a local inflammation
and to tissue remodelling (Leskinen et al. 2001, Garbuzenko et al. 2002). (Table 2. The
Mast Cell as an Effector Cell)
19
Table 2. The Mast Cell as an Effector Cell
Mediators Main pathophysiologic effects
Prestored
Biogenic amines
Epinephrine, dopamine, phenylalanine (not
synthesized, but taken up and stored)
Neuromodulation
Histamine Vasodilation/constriction, angiogenesis, mitogenesis, pain
5-Hydroxytryptamine (5HT, serotonin) Vasoconstriction, pain
Chemokines
IL-8, MCP-1, MCP-3, MCP-4, RANTES Chemoattraction
Enzymes
Arylsulfatases Lipid/proteoglycan hydrolysis
MMP 1-3, 9 Matrix degradation
Carboxypeptidase A Peptide processing
Chymase Tissue damage, pain, angiotensin II synthesis
Kininogenases Synthesis of vasodilatory kinins, pain
Phospholipases Arachidonic acid generation
Tryptase Tissue damage, inflammation, pain
Growth Factors
CSF, GM-CSF, b-FGF, NGF, TGF-β Growth of a variety of cells
Peptides
Chemotactic factors Infiltration of leukocytes
Corticotropin-releasing factor (CRH) Vasodilation, inflammation
Endorphins Analgesia
Kinins (bradykinin) Vasodilation, pain
Somatostatin (SRIF) Antiinflammatory
Substance P (SP) Inflammation, pain
Vasoactive intestinal peptide (VIP) Vasodilation
Proteoglycans
Chondroitin sulfate Cartilage synthesis, antiinflammatory, NGF stabilization
Heparin Angiogenesis, NGF stabilization
Hyaluronic acid Connective tissue synthesis, NGF stabilization
De novo synthesized
Cytokines
Interleukins (IL)-1,2,3,4,5,6,9,10,13,16 Inflammation, leukocyte migration, pain
IFN-γ, MIF Inflammation, leukocyte proliferation/activation
TNF-α Inflammation, vascular adhesion molecule expression
Arachidonic acid products
Leukotriene B4 (LTB4) Leukocyte chemotaxis
Platelet Activating Factor (PAF) Platelet activation & serotonin release
Prostaglandin D2 (PGD2) Vasodilation, pain
Leukotriene C4 (LTC4) Vasoconstriction, pain
Nitric Oxide (NO) Vasodilation, neurotransmission
CSF = colony-stimulating factor; IFNγ  interferon-γ; MIF = macrophage inflammatory factor; b-FGF = basic fibroblast
growth factor; NGF = nerve growth factor; TGF-β = transforming growth factor-β; TNF-α = tumor necrosis factor-α; SRIF
= somatostatin; GM-CSF = granulocyte macrophage-colony stimulating factor.
Adapted from Theoharides 2002
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2.3. Sensory nerve system
2.3.1. Introduction
The cell bodies of primary afferent neurons are located in the spinal (dorsal root) or cranial
sensory ganglia and send fibers in both the central and peripheral directions. The endings
of the peripheral fibers may be either receptors themselves or connected to special sensory
structures. Traditionally, the sensory nervous system has been thought to function as a
receptive and afferent system which reflexly activates effector systems and thereby enables
the organism to react to changes in the external and internal environment, i.e. when
something hot is touched by the hand, there is a reflex withdrawal of the limb (Henneman
1980). Over the past century, however, it has become increasingly clear that sensory nerves
also have an efferent motor function (Bayliss 1901). Moreover, later studies have
confirmed that sensory nerve fibers take part in local effector systems which are involved,
for example, in inflammatory responses (neurogenic inflammation) to tissue irritation and
injury (Chapman et al. 1964, Jancso et al. 1967, Szolcsanyi 1988). The term 'axon reflex'
was introduced to describe the conjunction of afferent (orthodromic) and efferent
(antidromic) conduction of impulses (Bayliss 1901). Nerve-derived neuropeptides or
neurotransmitters are involved as mediators in both these functions (Lembeck and Holzer
1979).
2.3.2. Sensory nerves and neurogenic inflammation
Neurogenic inflammation is the summation of the inflammatory effects of stimulation of
peripheral nerves and is characterized by increased vascular permeability and plasma
leakage due to activation of neurokinin-1 (NK-1) receptors by substance P (SP) released
from sensory nerve fibers (McDonald et al. 1996). Other neuropeptides, e.g. vasoactive
intestinal peptide (VIP) and calcitonin gene-related peptide (CGRP), released by sensory
nerves (VIP may be localized to parasympathetic and sensory nerves) also act to amplify
inflammation, and increased vascular permeability and the chemotactic effects of
neuropeptides result in accumulation and activation of leukocytes (Abelli et al. 1992,
Teresi et al. 1996, Hogaboam et al. 1997), macrophages (James and Nijkamp 2000,
Marriott et al. 2001) and mast cells at the site of inflammation (Forsythe et al. 2000, Saban
et al. 2002).
Inflammatory changes mediated by sensory nerves have been reported in many tissues and
organs. (Saria et al. 1983, McDonald et al. 1996, Gyorfi et al. 1992, Reynolds et al. 1997).
It is conceivable that neurogenic inflammation may also occur in the central nervous
system, most of the gastrointestinal tract, skeletal muscle and heart, because histochemical
studies on these tissues have demonstrated that there are abundant nerve fibers containing
vasoactive peptides, such as CGRP, SP and VIP (Mulderry et al. 1985, Owman et al. 1990,
Crowe et al. 1992, Shulkes 1993, Rubino and Burnstock 1996).
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2.3.3. Neuropeptides: substance P (SP), calcitonin gene-related peptide (CGRP) and
vasoactive intestinal peptide (VIP)
Studies using anatomical, histochemical and immunological methods have revealed the
presence of a variety of peptides in afferent neurons. Among the neuropeptides that occur
in sensory nerve endings are substance P (SP), vasoactive intestinal peptide (VIP) and
calcitonin gene-related peptide (CGRP). However, VIP is more often present in the
parasympathetic nerve fibers than in somatosensory C- fibers (Wakisaka 1990). From
functional evidence it appears that SP, CGRP and VIP also play mediator or transmitter
roles. These regulatory neuropeptides normally consist of five to 40 amino acid residues,
and the peptide precursors are produced in the nerve cell bodies (Wallengren 1997). The
precursor protein is packaged into granules/vesicles in the Golgi area, and the active
peptide is generated through proteolysis in the secretory organelle, being ready for release
by the time it reaches the nerve terminal (Ekström 1987).
2.3.3.1. Substance P (SP)
Substance P (SP) is the most extensively studied and most potent member of the tachykinin
family. SP is a neurotransmitter that modulates a number of important sensory and
immunological functions (Gilbert and Payan 1991, Black 1994), including nociception and
inflammation (Lynn 1992). Substance P is present in primary sensory nerves that have
their cell bodies in the spinal and trigeminal ganglia (Cuello et al. 1978, Quartu et al.
1992). SP has also been identified in non-neuronal cell types, including murine
macrophages (Pascual and Bost 1990, Bost et al. 1992), human endothelial cells (Linnik
and Moskowitz 1989, Milner et al. 1990), eosinophils (Aliakbari et al. 1987), and Leydig
cells of human and mouse testis (Chiwakata et al. 1991). The autocrine regulation of SP
gene expression is suggested by the presence of specific SP receptors on the surface of
monocytes and the ability of macrophages to produce SP. The murine macrophage line
(P388D1) not only was responsive to the neuropeptide at low concentrations (Kimball et
al. 1988) but also produced SP (Pascual and Bost 1990).
Furthermore, substance P stimulates mitogen-induced proliferation of lymphocytes in vitro
(Stanisz et al. 1986). SP also increases lymphocyte traffic from lymph nodes to the
periphery in vivo (Moore et al. 1989) and may have a role in controlling traffic through the
high endothelial venules (Moore 1984). This effect is long-lasting and acts preferentially
on CD4+ (helper) T lymphocytes. SP enhances immunoglobulin production by cloned B
lymphoma cells (Pascual et al. 1991, Bost and Pascual 1992). SP stimulates human
peripheral blood monocytes to produce inflammatory cytokines, including IL-1, IL-6,
IL-10, IL-12, and TNF-α (Lotz et al. 1988, Laurenzi et al. 1990, Lee et al. 1994, Ho et al.
1996, Kincy-Cain and Bost 1997). These cytokines play important roles in the regulation
of various inflammatory reactions.
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2.3.3.2. Calcitonin gene-related peptide (CGRP)
CGRP is a major constituent in the sensory nervous system and has been found in sensory
neurons in the trigeminal ganglion and in the spinal ganglia (Edvinsson 2001). Like
substance P, CGRP is a pro-inflammatory factor and it is also thought to be involved in
neurogenic inflammation. (Brain et al. 1985). Moreover, in sensory nerve cell bodies
CGRP usually co-exists with SP (Lundberg et al. 1985) and is commonly found in nerves
that terminate at sites close to blood vessels, suggesting a role in the control of blood flow.
Indeed, it is well established that CGRP relaxes the major human blood vessels (Franco-
Cereceda 1988, Edvinsson et al. 1998, Wang et al. 1991). There is evidence that CGRP
receptors are expressed on inflammatory cells such as monocytes, macrophages, mast cells,
and lymphocytes (Levite 2000). Furthermore, CGRP directly induces a marked secretion
of IL-2, interferon-, IL-4, and IL-10 from T cells (Levite 1998) and contributes to
activation of macrophages (Tang et al. 1998).
Two subtypes of CGRP receptors termed CGRP-R1 and CGRP-R2, have been identified.
(Aiyar et al. 1996). CGRP induces vasodilation via CGRP-R1 receptors (Lundberg 1996).
CGRP also potentiates the plasma leakage induced by tachykinins in the skin and in the
airways (Brain and Williams 1985, Gamse and Saria 1985).
When injected into human skin, CGRP induces slowly developing local reddening
(duration of several hours) (Wallengren et al. 1987). Although SP and CGRP may be
released concomitantly from the same nerve fibers, they seem to differ from each other in
their duration of action, CGRP being more long-acting. In the immediate phase of
inflammation, it is likely that SP and histamine, by inducing a triple response, play crucial
parts. Thus, CGRP may play a greater part in the more prolonged stages of inflammation
(Wallengren 1997).
CGRP also has potent cardiovascular effects in animals and humans, which include
positive inotropic and chronotropic actions, systemic vasodilation, and hypotension.
(Franco-Cereceda 1988, Maggi 1995, Poyner 1992). Marked changes in plasma CGRP
concentration occur in congestive heart failure (Poyner 1992), septic shock (Griffin et al.
1992), but not in acute myocardial infarction (Wahrborg et al. 1999).
2.3.3.3. Vasoactive intestinal peptide (VIP)
Vasoactive intestinal peptide (VIP) is produced by neurons in different areas of the central
and peripheral nervous systems (Said and Rosenberg 1976, Fuxe et al. 1977) and by
endocrine cells such as the pituitary lactotrophes and cells of the endocrine pancreas
(Davidson et al. 1996). Furthermore, VIP has been identified in the primary and secondary
lymphoid organs, in the blood vessels throughout the body, in the intestinal and respiratory
tracts, and in the skin (Goetzl et al. 1998). Moreover VIP is also present in inflammatory
and immune cells (Cutz et al. 1978, Gomariz et al. 1990). Although VIP has been
extensively reported to regulate a wide variety of functions, participating in control of the
homeostasis of the immune system (Gomariz et al. 2001), its main role is probably as a
potent anti-inflammatory factor. The anti-inflammatory properties of VIP are exemplified
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by its ability to inhibit several macrophage functions, including phagocytosis, respiratory
burst, and chemotaxis (De la Fuente et al. 1996), and also by inhibiting T cell proliferation
and decreasing lymphocyte migration (Delgado et al. 1995). VIP has also been reported to
inhibit the production of pro-inflammatory cytokines such as TNF-α, interferon-_ (IFN-_),
IL-6, and IL-12 (Delgado et al. 1999b, Delgado et al. 1999d, Martinez et al. 1998, Delgado
et al. 1999a), to reduce the activity of inducible nitric oxide synthase (NOS) (Delgado et al.
1999a), and to enhance the production of the anti-inflammatory cytokines IL-10 and IL-
1Ra (Delgado et al. 1999c, Delgado et al. 2001).
The concentrations of VIP are increased in the serum of patients with septic shock
(Brandtzaeg 1989), in nasal secretions (Tonnesen et al. 1987), and in bronchoalveolar
lavage fluids of allergic patients after challenge (O'Donnell et al. 1994). Furthermore, VIP
levels are higher in the skin of patients with atopic dermatitis and psoriasis than in those
with normal skin (Delneste et al. 1999).
2.3.4. Sensory nerves and mast cells
The close contact between mast cells and nerve endings has been well established in both
rodents and humans. Mast cells are found in close apposition to peripheral nerve endings,
especially to nonmyelinated primary sensory nerve endings and autonomous nerve endings
in a variety of tissues (Arizono et al. 1990, Bienenstock et al. 1991, Johnson and Krenger
1992). This close contact is best studied in the skin (Naukkarinen et al. 1996), respiratory
tract (Undem et al. 1995) and gastrointestinal tract (McKay and Bienenstock 1994), the
major body sites at which a challenge with foreign antigens occurs. The presence of mast
cells in the skin next to nonmyelinated sensory fibers has been known for many years
(Olsson 1968). These nerve fibers contain among others SP, CGRP or VIP (Naukkarinen et
al. 1996). Similarly, in the respiratory tract, mast cells are located near by the airway
epithelium, where CGRP and SP-containing sensory nerve fibers are abundant.
Furthermore, mast cells are often situated in the close vicinity of the vasculature (Kaartinen
et al. 1996a, Hayashi et al. 2001).
Many neuropeptides, including SP, CGRP and VIP, can activate isolated mast cells, and
there is substantial evidence that they can activate mast cells in tissues as well, either when
applied directly (Ebertz et al. 1987, Church et al. 1989), or when released from activated
sensory nerves (Skofitsch et al. 1985, Dimitriadou et al. 1991). Furthermore, in many
animal studies capsaicin has been used to destroy SP-containing sensory nerves. In treated
animals, sensory nerve stimulation failed to cause mast cell degranulation suggesting that
neuropeptides, secreted by the sensory nerve fibers, involve in the mast cells activation
(Alving et al. 1991).
2.4. Complement system
The complement system comprises approximately 30 glycoproteins present in serum in the
form of components, factors, or other regulators and/or on the surface of different cells in
the form of receptors. The proteins of the complement system can be produced by a variety
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of cells but the main production takes place by hepatocytes in the liver (Alper et al. 1969).
The complement system participates in defense against microbes, in the generation of
inflammation, and in the clean-up of tissues from, for example apoptotic cells (Densen
2000). Proteins of the classical pathway are called components and are symbolized by the
letter C followed by a number, for example, C3. Proteins of the alternative pathway are
called factors and are symbolized by letters, such as B. These components were named in
the order in which they were first described, consequently, the sequence of activation is not
in numerical order. The interaction of the complement system components produces a
cascade effect, in which each step produces an amplification of events that leads to a much
larger number of activated particles in the next step.
2.4.1. Complement activation
Activation of the complement cascade results in cleavage of complement proteins (Figure
2) that leads to the formation of C5b-9 called the membrane attack complex (MAC) on the
plasma membrane of target cells by self-assembly of the complement molecules named
C5b, C6, C7, C8 and C9. These molecules form a channel-like structure where
C5b/C6/C7/C8 form the cell surface anchor to which 10-15 C9 molecules bind, forming a
channel in the cell membrane (Müller-Eberhard 1988). The activation of these complement
factors leads to the terminal pathway, and also to formation of split products that have
strong proinflammatory properties, namely C3a, C4a and C5a, or that can function as
opsonins, namely C3b, iC3b, C3d and C4b and C4d.
There are three pathways which can initiate complement activation: the classical pathway,
the alternative pathway and mannan-binding lectin (MBL). All these pathways are directed
at the single most important step in the activation cascade, the cleavage of C3, in which
C3a is cleaved from C3 by a C3 convertase (C4bC2a) initially formed from the
classical/MBL pathways or C3bBpP in the alternative pathway (Figure 2). The remaining
C3b fragment can activate the terminal pathway by associating with C3 convertase to form
C5 convertase, the enzyme that cleaves C5 into C5a and C5b, where C5a acts as a
chemoattractant provoking inflammation and C5b functions as an anchor to form C5b-9
(MAC). C3b can also be further processed into iC3b, C3c, C3d(g) and C3d (Densen 2000).
2.4.1.1. The classical pathway (CP)
The classical pathway of complement activation is a mediator of the specific antibody
response. It is triggered by antigen-bound antibody molecules. The classical pathway is
initiated when C1q binds to the Fc fragments of IgM or multiple molecules of IgG. This
binding causes the activation of two C1r molecules, which in turn activate two molecules
of C1s. C1s is a serine proteinase that cleaves C4a and C4b from C4. The cleavage product
C4b and C2 form the C4bC2 complex (Dodds et al. 1996). This complex is further cleaved
by active C1s to C4b2a, the classical C3 convertase in which the C2a part is able to cleave
C3 to C3a plus C3b and C5 to C5a plus C5b, respectively. C5b binds to a foreign cell
membrane and initiates the action of other complement components (C6 - 9) that lead to
the membrane attack complex (Densen 2000).
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2.4.1.2. The alternative pathway (AP)
In the alternative activation pathway, the complement system is capable of acting
independently of other parts of the immune system. Typically, antibodies are not involved
in the alternative pathway. This pathway can be activated by nonimmune activators, for
example, repeating polysaccharide units or the LPS found on the cell walls of some
microbes. This pathway differs from the classical pathway in that it has substitutes for the
early acting C1, C4, and C2 components. Therefore, it can directly initiate the reactions of
the late-acting C3-C9 components. In plasma, the alternative pathway is continuously
activated at a low rate by spontaneous hydrolysis of C3 to C3(H2O). C3(H2O) has a
molecular structure similar to C3b (except that the C3a part is still present) and is able to
form a transient C3 convertase (C3(H2O)Bb) with factor B which has become cleaved to
Bb by factor D. Following cleavage of C3 by this initial C3 convertase, by the classical
pathway C3 convertase or by certain other proteases, the C3b formed becomes the subunit
of the actual alternative pathway C3 convertase C3bBb. In addition to C3, the C3bBb
convertase can also cleave C5. The activity of the convertase can be enhanced by
properdin, which stabilizes the bimolecular C3bBb complex. This pathway is also
sometimes called the properdin pathway (Lachmann 1998).
2.4.1.3. The lectin pathway (LP)
The lectin pathway closely resembles the classical pathway. Instead of C1 the pathway is
initiated by mannose binding lectin (MBL) which has structural homology to C1q. MBL
binds to mannose and N-acetylglucosamine structures on the target surface. When MBL
binds to its target, it is able to interact with two serine proteases known as MASP 1 and
MASP 2 (mannan-binding lectin-associated serine proteinase), which are analogous to C1r
and C1s. The serine proteases cleave C4 into C4b and C4a, and from that point onward, the
lectin pathway is identical to the classical pathway and leads to the activation of the
terminal pathway (Medzhitov and Janeway 2000).
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Figure 2. Activation of the complement system and generation of C3a and C5a
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2.4.1.4. Anaphylatoxins C3a and C5a and their receptors
Complement activation via all three pathways leads to generation of small bioactive
molecules, anaphylatoxins C3a and C5a. Some enzymes like plasmin, kallikrein, and
leukocyte lysosomal enzymes, and bacterial proteases may also directly cleave C3, C4 and
C5 (Kirschfink and Borsos 1988, Gardinali et al. 1992). The anaphylatoxins C3a and C5a
can act as anaphylatoxins and chemotaxins (Hugli and Muller-Eberhard 1978, DiScipio
1992). They are capable of acting on their target cells by binding to and activating highly
ligand-specific membrane receptors belonging to the family of seven transmembrane
domain G-protein-coupled receptors. Thus, these anaphylatoxins can also regulate
inflammatory functions by interacting with their receptors, C3aR and C5aR (Ember and
Hugli 1997, Gerard and Gerard 1991, Ames et al. 1996). Indeed, the expression of both
C5aR and C3aR is greatly increased during inflammation, as has been demonstrated in the
brain (Gasque et al. 1997, Gasque et al. 1998).
2.4.1.5. Distribution of C3aR and C5aR
C3aR and C5aR are present on myeloid cells such as macrophages, neutrophils (Martin et
al. 1997), eosinophils (Zwirner et al. 1999b), basophils (Kretzschmar et al. 1993, Fureder
et al. 1995), and mast cells (Fureder et al. 1995, Legler et al. 1996). Recently, C5aR has
also been found in tubular epithelial and mesangial cells of the kidney (Braun and Davis
1998) and in hepatocytes (Haviland et al. 1995, Schlaf et al. 1999), and both receptors have
been detected on neurons and glial cells of the CNS (Davoust et al. 1999, Gasque et al.
1997, Gasque et al. 1998). In the lung, northern blot analysis of mRNA from human (Ames
et al. 1996, Gerard et al. 1993), baboon (Haviland et al. 1995), mouse (Haviland et al.
1995, Hsu et al. 1997), rat (Fukuoka et al. 1998, Akatsu et al. 1997), and guinea pig
(Fukuoka et al. 1998) have revealed the presence of C3aR and C5aR mRNA transcripts.
Studies have also documented the presence of C5aR on bronchial and alveolar epithelial
cells as well as on vascular endothelial and smooth muscle cells (Haviland et al. 1995).
2.4.1.6. The effects of C3a and C5a
C3a and C5a can trigger contraction of smooth muscle, increase the permeability of small
blood vessels, and regulate vasodilation (Vogt 1986, Drouin et al. 2001). These
anaphylatoxins can stimulate a respiratory burst in macrophages (Murakami et al. 1993,
Fischer et al. 1995), neutrophils (Ehrengruber et al. 1994, Pospisil and Pelclova et al.
1994), and eosinophils (Elsner et al. 1994). Both C3a and C5a can induce chemotaxis of
mast cells (Nilsson et al. 1996, Hartmann et al. 1997), and also trigger the mast cell and
basophil release of mediators already preformed in their granules, e.g. histamine, platelet-
activating factor (PAF), and tumor necrosis factor-α (TNF-α), IL-1, IL-3, IL-4, IL-5 and
IL-6 or newly synthesized through the metabolism of arachidonic acid, e.g. leukotrienes
and prostaglandins (Schulman et al. 1988, el-Lati et al. 1994, Burgi et al. 1994, Baumann
et al. 2001).
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C3a can also stimulate serotonin release from platelets (Fukuoka and Hugli 1988) and
modulate synthesis of IL-6 and TNF-α by B lymphocytes and monocytes (Fischer et al.
1997, Fischer et al. 1999). C5a is a potent chemotactic molecule for macrophages (Aksamit
et al. 1981), neutrophils (Ehrengruber et al. 1994, Yancey et al. 1989), T lymphocytes
(Nataf et al. 1999), and basophils (Lett-Brown and Leonard 1977). Furthermore, this
anaphylatoxin can cause secretion of proinflammatory cytokines from macrophages
(Goodman et al. 1982, Ember et al. 1994), and also T cell proliferation (Morgan et al.
1983).
2.4.1.7. Complement activation products in atherosclerotic coronary arteries
Previous studies have shown that activated components of the complement cascade are
present in atherosclerotic lesions in human arteries. Atherosclerotic plaques have also been
shown to contain deposits of C1, C3, C3, C4 and C5b-9 complexes (Vlaicu et al. 1985b,
Niculescu et al. 1987, Torzewski et al. 1997), whereas blood vessels of newborns do not
have complement deposits (Schäfer et al. 1986). The degree of complement activation in
the atherosclerotic lesions in an immunofluorescence study (Vlaicu et al. 1985a), as well as
the amount of C5b-9 quantified in an ELISA assay (Niculescu et al. 1987), was shown to
correlate with the severity of the lesions. Furthermore, development of atherosclerosis was
retarded in rabbits deficient in C6, suggesting that, in this animal model, activated
complement components play a direct causal role in atherosclerosis (Schmiedt et al. 1998).
Complement activation may exacerbate atherosclerosis by covalent deposition of C3b and
its activation fragments, which serve as ligands for phagocytes and activate the cells
(Takizawa et al. 1996), and by generating the membrane attack complex C5b-9, which may
induce expression of adhesion molecules on endothelial cells, activate various intimal cells
to secrete proatherogenic cytokines, or cause necrosis or apoptosis of intimal cells (Morgan
1989, Hattori et al. 1989). One unexplored mechanism by which complement may
modulate inflammation in the arterial intima is stimulation of the intimal cells by the two
potent anaphylatoxins C3a and C5a, which are released during complement activation.
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3. AIMS OF THE STUDY
Mast cells are present in human coronary arteries. Increased numbers of these cells are
found in human advanced atherosclerotic coronary plaques, whether stable or ruptured, but
the majority of coronary mast cells are found in the adventitial layers of these arteries.
Mast cells are pluripotent effector cells which contain a multitude of vasoactive
compounds and also large amounts of serine proteinases. Thus, they may contribute to
coronary contraction and degradation of the plaques, so predisposing them to rupture. For
their effects, the mast cells have to become activated and secrete their vasoactive
compounds and proteases. Thus, the general aim of this work was to elucidate the potential
mechanisms which may activate mast cells in human coronary arteries. It is known, that
mast cells can be activated by other inflammatory cells (macrophages and T lymphocytes),
by the transmitters secreted by sensory nerves, and by anaphylatoxins generated during
complement activation. The specific aims of this immunohistochemical work were to study
in human atherosclerotic coronary arteries:
1. The presence of adventitial mast cells and other inflammatory cells (I)
2. The association of adventitial mast cells and sensory nerve fibers (II)
3. Evidence for complement activation in ruptured coronary plaques (III)
4. Expression of anaphylatoxin receptors in coronary mast cells and other inflammatory
cells (IV).
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4. MATERIALS AND METHODS
4.1. Autopsy material and tissue preparation
For studies I, II, III, and IV, autopsy material was obtained from the Department of
Forensic Medicine, and for studies I and III from the Department of Pathology, University
of Helsinki. In addition, coronary arteries were freshly obtained during heart
transplantation from 2 patients with dilated cardiomyopathy from the Department of
Thoracic and Cardiovascular Surgery, Helsinki University Hospital. Autopsy samples of
the left anterior descending coronary artery were collected from 39 cases of death from
acute myocardial infarction and from 76 cases of death from other reasons than coronary
disease, during 1996-2001.
The following protocol was used for obtaining various segments from the infarct-related
left anterior descending coronary arteries (LAD): infarcted myocardium was first identified
at autopsy with nitro blue tetrazolium enzyme staining and confirmed by histology. To find
three segments (segment with ruptured plaque, segment with nonruptured plaque, and
segment with normal intima) from the infarct-related coronary artery (all were left
anterior descending coronary arteries), the following uniform dissection protocol was
employed. The coronary artery was cut into 3 to 5 mm segments, starting from the origin
of the LAD coronary artery and moving distally until an occluded (thrombosed) lumen and
a suspected ruptured plaque were found. Similar segments were then cut distally until a
nonthrombosed plaque was found. These segments were located 2 to 4 cm distal to the
segment with ruptured plaque. Finally, similar segments were cut distally from the segment
with the nonthrombosed plaque, until a segment without visible atherosclerotic changes
was found. These segments with normal intima were located 2 to 4 cm distal of the
segment with the nonthrombosed plaque. The same protocol for obtaining three segments
was adapted for the LAD coronary arteries from patients who had died from non-coronary
causes.
For study I the specimens were fixed in Carnoy´s fluid (60% ethanol, 30% chloroform, and
10% glacial acetic acid) for 24 h hours and embedded in paraffin. For studies II, III, and
IV, the segments were embedded in OCT medium and snap-frozen in liquid nitrogen. For
study IV, 8 samples were also fixed in 10% neutral-buffered formalin and embedded in
paraffin. Then, sections 8 16  µm thick were cut from frozen and sections 4 µm thick
from paraffin embedded coronary segments, respectively.
4.2. Definition of the lesions
To evaluate the atherosclerotic involvement of the left anterior descending coronary
arteries, the specimens were stained with hematoxylin and eosin and, evaluated
microscopically using the criteria established by the American Heart Association (Stary et
al. 1994, Stary et al. 1995). The normal intima in the segments without visible
atherosclerotic changes exhibited variable thickness and moderate overall cellularity. In
some cases, isolated foam cells could be identified, corresponding to an initial or type I
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lesion. Type II lesions (designated fatty streaks) consisted primarily of collections (layers)
of foam cells. Type III lesions contained scattered pools of extracellular lipid. Type IV
lesions contained a larger confluent core of extracellular lipid. Type V lesions had
prominent newly formed fibrous connective tissue. In some type V lesions, the new
prominent fibrous tissue accounted for more of the thickness of the lesion than did the
underlying lipid accumulation.
In study I, the following types of nonruptured lesions were found: 2 lesions of type III, 11
lesions of type IV, and 4 lesions of type V; in the study II: 9 type II, 8 type III, 11 type IV
lesions; in the study III: 1 type III, 12 type IV, and 3 type V in the infarct patient group,
and 7 type IV and 3 type V lesions in the control autopsy cases and, in study IV: 1 type II,
2 type III, and 16 type IV lesions.
In study I, 17 and in study III 16 lesions had plaque rupture. In studies I, II and IV, the
numbers of control coronary samples with normal intima (type 0-I lesion) were 17, 24 and
8, respectively. For all the studies (I-IV) we collected new coronary samples, i.e. no
sample was used for more than one study.
4.3. Immunohistochemistry
For immunohistochemistry, paraffin sections were dewaxed in xylene and rehydrated in a
graded series of ethanol solutions. Endogenous peroxidase activity was inhibited by
incubation with 0.6% H2O2 in methanol. Frozen sections were fixed in acetone. In the
staining procedures the following primary antibodies, seen in table 3, were used.
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lymphocytes were stained by the avidin-biotin complex method with DAB and smooth
muscle cells by the direct immunoperoxidase method with AEC.
In study II, frozen sections were stained for sensory nerves and mast cells, using a
histochemical double labelling method. For identification of the adventitial nerves,
cryosections were incubated in a cocktail of monoclonal antibodies (1:50) against 68, 160
and 200 kD neurofilament proteins (NF), after which NF was detected using a streptavidin-
biotin peroxidase method. Mast cells were stained enzyme histochemically for tryptase.
Mast cells in contact with sensory nerves were quantified morphometrically and were also
studied by confocal laser scanning microscopy. For fluorescence microscopy the FITC-
labeled goat anti-mouse immunoglobulin (DAKO, Glostrup, Denmark) was applied as
secondary antibody. Tryptase was stained with a monoclonal anti-tryptase antibody (G3)
combined with TRITC-labeled swine anti-rabbit immunoglobulin (DAKO) as the second
layer. Coronary arteries freshly obtained during heart transplantation (2 patients) were
stained for the neuropeptides SP, CGRP, and VIP followed by the biotin-conjugated goat
anti-rabbit immunoglobulin (Vectastain Elite ABC Kit, PK-601; Vector laboratories,
Burlingame, California, U.S.A.).
In study III, frozen sections were stained for macrophages, T lymphocytes, mast cells (G3),
C5b-9 neoepitope, and iC3b. The primary antibodies were detected using the avidin-biotin
complex system (Vectastain ABC kit, Vector Laboratories) with AEC (Sigma) as
chromogen. For lipid staining, the sections were fixed with p-formaldehyde and stained
with oil red O (Lupu et al. 1987). The sections were then counterstained with methyl green
(Vector Laboratories) or hematoxylin and mounted in Permount. In samples for fluorescent
microscopy, the primary antibodies were detected using various isotype-specific Alexa-
conjugated secondary antibodies (Molecular Probes, Eugene, Oregon, U.S.A.; 1:200
dilution), the nuclei were stained with DAPI (Molecular Probes), and the sections were
mounted using SlowFade (Molecular Probes).
Finally, the sections were counterstained with hematoxylin (studies I, II, and IV) or methyl
green (study IV) and mounted.
4.4. Morphometric analysis and microscopic examination
In study I, the areas of the adventitia were measured by planomorphometry, using the
Global Lab Image software program at the Department of Electron Microscopy, University
of Helsinki, and the immunopositive cells (mast cells, T lymphocytes, and macrophages)
were counted in the measured areas at x 400 magnification. In study II, the numbers of
adventitial mast cells were counted in 10 grid fields (each 0,27 mm2). In study III, the
numbers of intimal mast cells were counted in the entire intimal area, which was defined
with the aid of the grids. In all three studies, the cell densities were expressed as numbers
of cells per mm2.
In study II, besides light microscopy, coronary sections were examined in a conventional
fluorescence microscope (Leitz Dialux 22, Leica Lasertechnik GmbH, Heidelberg,
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Germany) equipped with epifluorescence and appropriate filter sets for FITC and TRICT.
Then samples were studied in a confocal laser scanning microscope (Leica CLSM
Aristoplan, Leica Lasertechnik GmbH). A 75 mW argon-krypton ion-laser (Omnichrome,
Chino, California, U.S.A.) was used. The excitation wavelengths were 488 nm for FITC
and 568 nm for TRITC. Optical images were taken at 0.5 - 1.0 µm intervals for a total of
10 optical sections per scanning sequence. Photographs were taken directly from the video
monitor with a 35 mm camera.
In study IV, the samples for fluorescent microscopy were viewed and photographed with a
Nikon E600 fluorescent microscope (Nikon Instech Co, Kawasaki, Kanagawa, Japan)
equipped with appropriate fluorescent filters and a cooled CCD camera (Spot RT,
Diagnostic Instruments, Sterling Heights, Michigan, U.S.A.) .
4.5. Statistics
In study I, within-case comparisons were made of numbers of mast cells, macrophages,
and T lymphocytes between the segments with ruptured plaque, nonruptured plaque, and
normal intima. Poisson regression analysis was used to model the number of cells per unit
tissue area. The mast cell counts were arranged as contingency tables. The location of the
mast cells in the different coronary segments and the distance of the mast cells from the
media or the degree of degranulation formed the marginals of the tables. The independence
of the marginals was tested with log-linear models. Differences were considered
statistically significant when P< 0.05.
In study II, comparisons were made of the numbers of mast cells between the segments
with a normal intima (types 0-I) and with lesions of types II, III and IV. Poisson regression
analysis was used to model the number of cells per unit of tissue area. The mast cells in
contact with nerve fibers as a proportion of all mast cells was analyzed, using logistic
regression. Pairwise differences between sites (i.e. coronary segments with different
degrees of atherosclerosis) were tested with a Wald type test, using pairwise contrasts.
In study III, the densities of mast cells, macrophages, and T lymphocytes, and the extent of
staining for iC3b in atherosclerotic plaques were compared between ruptured and
nonruptured plaques of the same infarct-related coronary arteries and between nonruptured
plaques of MI patients and control cases, using the paired and the unpaired two-tailed
Students t test, respectively. Probability values <0.05 were considered statistically
significant.
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5. RESULTS
5.1. Mast cells in the adventitia of coronary arteries (I)
5.1.1. Quantitation of mast cells in the infarct-related coronary adventitia (I)
To be able to count the mast cells, the adventitia of coronary sections were stained with
tryptase. In the first study, coronary samples were collected from infarct-related coronary
arteries of 17 patients who had died in myocardial infarction (MI) and from 10 control
group patients who had suffered a noncardiac death. The series of coronary samples were
as followings: coronary segments with ruptured plaque (proximal segment), nonruptured
plaque (middle segment) and normal intima (distal segment) in the infarct-related coronary
artery from MI patients and three coronary segments (proximal, middle and distal
segments corresponding to the respective segments in the infarct-related arteries) with
normal intima without visible atherosclerotic changes from the patients of the control
group.
In the segments with plaque rupture, the densities of adventitial mast cells were
significantly higher (the average density being 98 mast cells/mm2) than in the segments
with nonruptured plaque (41 mast cells/mm2). These latter values, again, were significantly
higher than in the segments with normal intima (19 mast cells/mm2). The above trend was
observed in every patient studied. Thus, in the segments containing the culprit lesion
responsible for the infarction, the numbers of adventitial mast cells were, on average, 5-
fold higher than in the normal segments of the same coronary artery. In contrast, no such
trend was observed in the control coronary arteries (see study I, Figure 3), the densities of
the adventitial mast cells being roughly equal in all three segments, on average 9 cells/mm2
in the proximal segment (corresponding to the segment with plaque rupture); 8 cells in the
middle segment (corresponding to the segment with nonruptured plaque); and 10 cells in
the distal segment (corresponding to the segment with normal intima). Between the
segments with plaque rupture and the corresponding proximal segments of the control
coronary arteries, the densities of adventitial mast cells showed a 10-fold difference.
Interestingly, even in the normal segments of the infarct-related arteries, the mast cell
densities were 2-fold higher than in the corresponding segments of the control arteries (19
vs. 10 mast cells/mm2), suggesting that the entire adventitial layer of the infarct-related
coronary artery was affected by the inflammatory process.
5.1.2. Characterization of adventitial mast cells in the coronary arteries (I)
To characterize the mast cells in the coronary adventitia of the segments with plaque
rupture, segments with nonruptured plaque and segments with normal intima, coronary
samples were stained for tryptase and chymase by a double-labeling method (Kaartinen et
al. 1994b). The great majority of the adventitial mast cells contained chymase (in addition
to tryptase). Furthermore, in the segments with plaque rupture, a larger proportion of mast
cells contained chymase (the average was 87%) than in the segments with nonruptured
plaque (80%), or in those with a normal intima (66%). Interestingly, in the segments with
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plaque rupture the proportion of intimal mast cells containing chymase was significantly
lower (37%; Kovanen et al. 1995). However, it may be of importance in acute coronary
syndromes, that chymase, secreted upon mast cell degranulation, is able to convert
angiotensin I into angiotensin II, which is a potent vasoconstrictive compound (Urata et al.
1990). Sections of the infarct-related coronary arteries were also immunostained for
histamine, which is a potent trigger of abnormal vasoconstriction in atherosclerotic
coronary arteries. Only the mast cells in the adventitia stained positively for histamine (see
study I, Figure 4).
5.1.3. Degranulation of adventitial mast cells (I)
Degranulation of mast cells, a sign of mast cell activation, is needed for their effective
action on their environment. Indeed, a significant fraction of the mast cells in the
atherosclerotic coronary intima was found to be degranulated (Kovanen et al. 1995). To
estimate the degree of degranulation of the mast cells, light microscopy was used at high
magnification (x1000) and every adventitial mast cell (4312 mast cells in the segments
with rupture, 1346 in the segments with intact plaque, and 712 in the segments with a
normal intima) present in the specimens was studied. At this magnification, the
extracellular granules were also clearly visible, and we were able to count the numbers of
extracellular granules in the vicinity of their parent mast cells in the various segments of
the infarct-related coronary arteries. The proportion of adventitial mast cells with extensive
degranulation (more than 5 extracellular granules) was significantly higher in the segments
with plaque rupture (the average proportion of degranulated mast cells was 49 %) than in
those with nonruptured plaque (17 %) or in those with a normal intima (11 %). In contrast,
in the segments with plaque rupture, the proportion of resting adventitial mast cells (no
extracellular granules) was significantly lower (on average 6 %) than in the segments with
nonruptured plaque (26 %) or in the normal segments (43%) (see study I, Figure 5).
5.1.4. Mast cells and vasa vasorum (I)
Mast cells contain many factors that stimulate angiogenesis, i.e. histamine (Marks et al.
1986), heparin (Norrby and Sorbo 1992), neutral proteases (chymase and tryptase)
(Meininger and Zetter 1992), IL-8, TNF-α, basic fibroblast growth factor (bFGF; Norrby
1997), and vascular endothelial cell growth factor (VEGF; Boesiger et al. 1998), and they
have been shown to induce formation of microvessels in tumor growth (Roche 1985) and
wound healing (Trabucchi et al. 1988). Indeed, in many organs and under physiological
conditions, mast cells close to capillaries are numerous (Eady et al. 1979, Rhodin and
Fujita 1989, Rakusan et al. 1990). These cells have also been found in human coronary
plaques in close proximity to neovascular vessels (Kaartinen et al. 1996a).
To study the relation between adventitial mast cells and vasa vasorum in the three
segments of the infarct-related coronary arteries, the distances of the mast cells from the
nearest adventitial vessel were measured. In every segment, the majority of the mast cells
were found to be located in the close vicinity (at distances < 30 µm) of a small vessel.
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These small vessels form plexus, called vasa vasorum, and supply blood to the medial
smooth muscle cells. Furthermore, more than 40% of the adventitial mast cells were
located in the immediate vicinity of the media (at distances < 30 µm) (see study I, Figure
6). Interestingly, the proportion of adventitial mast cells adjacent to the media (at distances
< 30 µm) was significantly higher (on average 48%) in the segments with culprit lesion
than those with a normal intima (33 %).
5.2. Adventitial macrophages and T lymphocytes (I)
To identify and quantify T lymphocytes and macrophages in the adventitia of the various
segments of the infarct-related coronary arteries, the sections were stained with antibodies
against T lymphocytes and macrophages (see study I, Figure 7). In the segments with
ruptured plaque, the densities of adventitial T lymphocytes (the average density being 201
T lymphocytes/mm2) and macrophages (474 macrophages/mm2) were both significantly
higher than in the segments with nonruptured plaque (126 T lymphocytes/mm2; and 308
macrophages/mm2), which again were significantly higher than the corresponding values
in the segments with a normal intima (65 T lymphocytes/mm2 and 152 macrophages/mm2)
(see study I, Figure 8). Thus, the differences in density between these two types of
inflammatory cells paralleled those of mast cells. Interestingly, large numbers of
macrophages and occasional T lymphocytes were also present in the border zone between
the media and the adventitia, where the mast cell density was highest.
5.3. Sensory nerve fibers and mast cells in the coronary adventitia (II)
A close anatomical relationship between mast cells and sensory nerve fibers has been
found in a number of previous studies (Dimitriadou et al. 1990, Naukkarinen et al. 1996).
Furthermore, neurogenic activation of mast cells has been demonstrated in other tissues
(Skofitsch et al. 1985, Spanos et al. 1997). To investigate the association between mast
cells and the sensory nerve system in coronary arteries, 52 coronary samples were
collected from 22 unselected patients who had suffered a noncardiac death. These samples
with various types of intimal lesion were classified according to the AHA classification:
segments with advanced atherosclerotic lesion (type IV), intermediate lesion (type III and
II) and segments with a normal intima. Frozen sections of these segments were then
stained for tryptase-positive mast cells and neurofilament-positive sensory nerves using a
histochemical double labelling method.
In the coronary adventitia of segments with advanced atherosclerotic type IV lesions, the
densities of mast cells (see study II; Figure 3, panel A) and mast cell-nerve contacts (panel
B) (the average densities of mast cells being 104 cells/mm2 and mast cells in nerve
contacts 30/mm2) were significantly higher than in the segments with intermediate lesions:
type III lesions (79 and 24) and type II lesions (54 and 12) or segments with normal intima
(types 0-I)(31 and 4). In the above series of segments, the percentages of mast cells with
nerve contacts (panel C) were also higher in the more advanced lesions (28, 31, 21, and
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14% in types IV, III, II, and 0-I, respectively). Notably, sensory nerve fibers were not
found in the intimal layer of coronary arteries.
To be able to stain neurotransmitters, substance P (SP), vasoactive intestinal peptide (VIP),
and calcitonin gene-related peptide (CGRP), all potentially capable of stimulating mast
cells, we used coronary segments freshly obtained during heart transplantation (2 patients).
The nerve fibers contacting mast cells contained SP and CGRP (see study II Figure 4),
whereas only a few nerve fibers stained positive for VIP, which is more often present in
parasympathetic nerve fibers than in somatosensory C- fibers.
5.4. Mast cells in the intima of coronary arteries (III)
Mast cells were shown to accumulate in the shoulder region of human coronary atheromas
(Kaartinen et al. 1994a), the predilection sites of atheromatous rupture, and also at the site
of rupture in culprit lesions of MI patients. The densities of macrophages and T
lymphocytes were also highest in the area of rupture. Intimal mast cells were found to
contain two neutral proteases (all contained tryptase and many also contained chymase)
that are capable of triggering degradation of the extracellular matrix via activation of
matrix metalloproteinases (MMPs). Furthermore, at the sites of rupture of the plaque the
proportion of degranulated (activated) mast cells was 87%, compared to 38% in the
unaffected intimal areas (Kovanen et al. 1995).
The collected autopsy series comprising coronary artery specimens from 22 patients who
had died of anterior MI due to occlusion of the left anterior descending coronary artery and
from 10 control autopsy cases who had died of noncardiac causes but had an
atherosclerotic left anterior descending coronary artery. Next, we analyzed the total plaque
areas in the samples for the densities of inflammatory cells, and found a ~2-fold increase in
the average density of the three types of inflammatory cells in the ruptured as compared to
the non-ruptured plaques (on average: 11 vs 5 mast cells/mm2, macrophages 91 vs 43 and
T cells 58 vs 24). There were no statistically significant differences in the numbers of
inflammatory cells between the nonruptured plaques of the MI patients and the controls.
5.5. Complement activation products, iC3b and C5b-9 in the coronary intima (III)
To study whether and where complement is activated in advanced atherosclerotic lesions,
we stained coronary artery plaques for activated complement components. Coronary
segments without atherosclerotic changes (type 0-I lesion) obtained from control subjects
who died of a noncardiac cause failed to show or showed only marginal deposition of the
complement components iC3b or C5b-9. Stable (nonruptured) advanced atherosclerotic
plaques with a necrotic core and a thick fibrous cap (AHA type IV) showed signs of
complement activation (see study III; Figure 1). A relatively weak staining for iC3b was
found as a distinct layer adjoining the medial boundary, and also diffusely throughout the
atherosclerotic intima. Intensive staining for the terminal complement complex (C5b-9)
was found deep in the intima at the medial border in the plaque and some weak staining in
the superficial intima, but not in the nonatherosclerotic sector of the vessel wall or in
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nonatherosclerotic coronary arteries from the control autopsy cases (not shown). When the
atherosclerotic arteries were stained with Oil Red O, two patterns of lipid staining were
observed. A strong but diffuse staining was found at the border of the intima and the
media, where C5b-9 was also present; this staining pattern corresponds to that of
extracellular lipids. In addition, spotted staining for lipids was found in the macrophage-
rich area, presumably reflecting the intracellular lipids of foam cells.
We next studied complement activation in the ruptured coronary plaques (see study III;
Figure 2), focusing on whether activated complement components were present at the site
of plaque rupture. The staining for iC3b was strong at the sites of rupture and in the
superficial intima next to rupture, where inflammatory cells were also present, whereas the
staining for C5b-9 in these areas was weak. However, strong staining for C5b-9 was found
deeper in the intima, where inflammatory cells were absent. A similar strong staining for
iC3b and C5b-9 was found in the debris exposed in the necrotic lipid core of the ruptured
plaque.
In view of the difference in staining for iC3b between the nonruptured and the ruptured
plaques observed in the coronary arteries, a pairwise comparison was made of iC3b
staining between the two types of plaque in the 10 MI patients from whom both
nonruptured and ruptured plaques were obtained from the same infarct-related coronary
artery, to match patient-associated variables, such as previous diseases, medication,
duration of symptoms, and post-mortem time (see study III, Table 1). We found that
staining for iC3b was significantly stronger and more extensive in the ruptured than in the
nonruptured plaques (2.9+0.2 vs 1.9+0.3, p<0.01). There were no statistically significant
differences in the extent of staining for iC3b between the nonruptured plaques of the MI
and the control patients (see study III, Figure 3).
5.6. Anaphylatoxin receptors C3aR and C5aR in coronary arteries (IV)
When complement system is activated anaphylatoxins C3a and C5a are generated. These
anaphylatoxins act on their target cells by binding to and activating highly ligand-specific
membrane receptors, namely C3aR and C5aR. To study the presence of C3a and C5a and
their receptors in the coronary arteries, we collected 19 atherosclerotic segments and 8
nonatherosclerotic control segments from human left anterior descending coronary arteries
and immunostained the samples for C3aR and C5aR, for stable complement activation
products (C3d and C5b-9) as surrogate markers of C3a and C5a, and for the various cell
types present in the arterial intima.
Depositions of C3d and C5b-9 were hardly present in the normal coronary wall (type 0-I
lesion). Only in the medial layer could some deposition of C3d and C5b-9 be found.
Moreover, staining for both C3aR and C5aR was essentially negative. Similar results were
obtained in each of the 8 normal coronary samples studied (see study IV, Figure 1).
In atherosclerotic plaques, in clear contrast to the normal intima, apparent deposits of
complement products C3d and C5b-9 were present, indicating complement activation (see
study IV, Figure 1). Strong staining for C3d could be found both in the superficial intima
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also containing inflammatory cells, and deeper in the musculoelastic layer of the intima.
Some C5b-9 was also present in the area containing the inflammatory cells, whereas,
deeper in the intima, staining for C5b-9 was extensive. Positive immunostaining for C3aR
and C5aR, especially in intimal and adventitial areas containing inflammatory cells, was
found in all the coronary segments with early and advanced atherosclerotic lesions that
were studied. Thus, in atherosclerotic, but not in nonatherosclerotic, coronary intimas,
complement activation products and anaphylatoxin receptors C3aR and C5aR were
present.
To evaluate which types of cells expressed anaphylatoxin receptors C3aR and C5aR,
sections of coronary segments were stained by the double immunofluorescence method for
these receptors, and for the various cell types present in the arterial wall; namely mast
cells, macrophages, T lymphocytes, smooth muscle cells and endothelial cells.
Macrophages in the arterial wall expressed both C3aR and C5aR, whereas mast cells and
all other cells expressed only C5aR (see study IV, Figures 3, 4, and 5).
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6. DISCUSSION
6.1. Mast cells and their possible effects in the coronary arteries
In the first study we showed that in patients who had died of myocardial infarction, the
segments of the infarct-related coronary artery that included the plaque rupture responsible
for the infarction contained increased numbers of adventitial mast cells. Moreover, using
immunohistochemical methods, we found that the mast cells in the adventitia were the only
cells that contained histamine. The close relation between the media, the layer responsible
for the regulation of coronary artery tone, and the adventitial mast cells suggests that a
fraction of the histamine released from the stimulated adventitial mast cells diffuses
directly into the media. Furthermore, the close relation between the histamine-containing
mast cells and the vasa vasorum provides another possible route for released histamine to
reach the medial layer. Indeed, in human atherosclerotic coronary arteries the inflow from
the dense plexuses of microvessels, characteristic of the atherosclerotic coronary segments,
through the media into the atherosclerotic intima has been visualized by cinemicrographic
studies (Barger et al. 1984 and 1990). Moreover, microsphere studies have shown that, in
atherosclerotic coronary segments, the blood flow from the adventitia via the vasa vasorum
into the media is strongly (fivefold) increased (Heistad et al. 1986).
In the medial layer, histamine, by binding to the histamine-1-receptors on smooth muscle
cells, will cause these to contract (Toda 1987). In atherosclerotic coronary segments,
smooth muscle contraction in response to histamine is likely to be vigorous, since the
damaged endothelium may have lost its opposing vasodilatory capacity (Kalsner et al.
1984, Kaski et al. 1989.). Indeed, after intracoronary injection of histamine, contraction of
the coronary arteries was observed in the atherosclerotic segments, but not in the normal
areas of these arteries (Ginsburg et al. 1981 and 1984).
We found that most of the mast cells in the human coronary adventitia contain not only
tryptase, but also chymase. In vitro, chymase effectively converts angiotensin I into
angiotensin II. This angiotensin-converting enzyme (ACE) activity of chymase has been
suggested to play a major role in the generation of angiotensin II in the human heart (Urata
et al. 1990), although a recent study has demonstrated that its activity in vivo is likely to be
equal to or less than that of the classical ACE (Kokkonen et al. 1997). Angiotensin II
receptors are present in the medial smooth muscle cells of human coronary arteries (Ohishi
et al. 1996). Thus, the angiotensin II generated by the chymase released from adventitial
mast cells and entering the medial layer via diffusion or via the vasa vasorum could act
synergistically with histamine and aggravate local constriction of the infarct-related
coronary artery. The hypothesis that, in myocardial infarction, coronary spasm at sites of
plaque erosion or rupture is caused, at least partly, by coronary adventitial mast cells is
supported by the clinico-pathological observation of Forman et al. (Forman et al. 1985).
These investigators found that, in a patient who, after follow-up for several years, suffered
sudden cardiac death, the angiographically detected spastic segment of the left descending
coronary artery contained increased numbers of adventitial mast cells. Furthermore, the
concentrations of histamine in coronary circulation has been found to be elevated shortly
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before coronary spasms with ensuing attacks of angina (Sakata et al. 1996, Clejan et al.
2002).
In atherosclerotic coronary plaques the number of mast cells are high, especially in the
shoulder area of the plaque (Kaartinen et al. 1994a), the predilection site for plaque rupture
(Richardson et al. 1989). Furthermore, degranulated mast cells are present at the sites of
coronary atheromatous erosion or rupture in myocardial infarction. These mast cells have
been found to contain tryptase or tryptase and chymase, i.e. proteases, which directly
contribute to matrix degradation (Kanbe et al. 1999). In addition, these proteases have been
shown to activate the precursors of MMP-2 (gelatinase A; Lohi et al. 1992), MMP-9
(gelatinase B; Fang et al. 1996), collagenase, and stromelysin (Lees et al. 1994).The mast
cells in rupture-prone areas of human coronary atheromas also contain TNF-α (Kaartinen
et al. 1996b), a powerful proinflammatory cytokine that is able to stimulate the production
of MMP-9 (92-kD gelatinase) by macrophages (Saren et al. 1996). Moreover, activated
mast cells containing angiogenic factors are found around newly formed microvessels in
human coronary atheromas. In addition to inducing the formation of neovessels in the
atherosclerotic intima, it is possible that neutral proteases secreted by mast cells may also
injure the microvessels and thereby produce intraplaque hemorrhage and, ultimately,
influence plaque stability and remodeling (Kaartinen et al. 1996a). Taken together,
activated mast cells may contribute to coronary contraction and weakening of the plaque,
and so predispose to plaque rupture.
6.2. Potential mast cell activation mechanisms in the human coronary adventitia and
intima
To influence surrounding tissues, mast cells have to become activated and release
mediators from secretory granules. The mechanisms activating these cells are, however,
obscure. Thus, the crucial question regarding the role of mast cells in human coronary
arteries is: what regulates mast cell activation and degranulation in the coronary adventitia
and intima?
The best characterized immunologic stimulus of mast cells is the bridging of Fc_RI
receptors via binding of IgE-specific divalent antigens to IgE bound to the Fc_RI receptors.
This event leads to a calcium-dependent secretory process in which mast cell secretory
granule membranes fuse with the plasma membrane with ensuing formation of pores in the
membrane and release of the soluble granule contents into the extracellular space. If the
stimulation is strong enough, the cytoplasmic granules become exocytosed and release
their soluble components within the extracellular space, with formation of insoluble,
granule remnants. These may contain tryptase and can easily be detected in the vicinity
of the activated mast cells by staining for tryptase, as has been done in recent studies.
Apart from activation by means of Fc_RI, mast cells are also activated by cross-linking of
surface FcγRIII molecules, by opiates, and by complement proteins (the anaphylatoxins
C3a, C5a), neuropeptides (VIP, CGRP and SP), the superoxide anions, radio-contrast
media, oxidized low-density lipoproteins (oxLDL), histamine-releasing factors secreted by
T lymphocytes and monocytes/macrophages, chemokines (MCP-1, -2, -3, and MIP-1), and
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bacterial infection. This suggests multiple pathways of mast cell activation in
atherosclerotic coronary arteries also (Metcalfe et al. 1997). Thus, the present work
attempts to unravel some of the potential activation mechanisms of mast cells in
atherosclerotic human coronary arteries.
6.2.1. T lymphocytes and macrophages co-localize with mast cells in coronary
arteries (I)
In the adventitia of the coronary segments with plaque rupture, as in the intima, the mast
cells often resided in areas where other inflammatory cells were also present (study I). T
lymphocytes and macrophages in such areas may secrete histamine-releasing factors
(Sedgwick et al. 1981, Liu et al. 1986, Alam et al. 1994, Tamura et al. 1999, Zhao et al.
2001), which, in turn, could stimulate mast cells to degranulate. Mast cells are also found
to degranulate in response to direct contact with activated T cells and to produce TNF-α
(Bhattacharyya et al. 1998). This direct contact between activated T cell membranes and
mast cells is also shown to cause a marked increase in the release of MMP-9 from human
mast cells. However, anti-TNF-α mAb inhibits the T cell membrane-induced release of
MMP-9, indicating a possible autocrine regulation of MMP-9 release by mast cell TNF-α
(Baram et al. 2001). Thus, it is likely that T lymphocytes and macrophages, which reside in
the close physical proximity to mast cells, can cause activation and degranulation of mast
cells not only in the intima but also in the adventitia of human coronary arteries.
6.2.2. Association between adventitial mast cells and sensory nerve fibers (II)
A number of investigations have shown that a close anatomical relationship exists between
mast cells and sensory nerve fibers in different human tissues. These include the adventitia
of the temporal arteries (Dimitriadou et al. 1990), the skin (Naukkarinen et al. 1996), the
glomus (Wiesner-Menzel et al. 1981), the nasal mucosa (Gauci et al. 1994 ), the bladder
(Spanos et al. 1997, Pang et al. 1995), and the gastrointestinal tract (McKay and
Bienenstock 1994).
We identified mast cells and nerve fibers in the adventitia of coronary arteries, and found
that contacts between adventitial mast cells and nerve fibers were more frequent in
atherosclerotic segments than in the control segments (study II). The nerve fibers in contact
with adventitial mast cells contained SP and CGRP. These neuropeptides can activate
isolated mast cells, and there is substantial evidence that they can activate mast cells in
tissues as well, either when applied directly (Ebertz et al. 1987, Church et al. 1989), or
when released from activated sensory nerves (Skofitsch et al. 1985, Dimitriadou et al.
1991). Great numbers of macrophages and T lymphocytes are present in the adventitia of
coronary arteries with advanced plaques. Excitation of sensory nerves by local
inflammation has been described (Lindholm et al. 1987, Barnes et al. 1986, Weihe et al.
1988) and could thus provide a mechanism by which other inflammatory cells activate
adventitial mast cells. Moreover, since mast cell histamine (Martins et al. 1991) and
tryptase (Steinhoff et al. 2000) can excite sensory neurons, a self-perpetuating axon reflex-
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mediated activation of mast cells may ensue in the inflamed adventitia. Such local axon
reflex mechanisms have been considered to play a role in the inflammatory pathogenesis of
asthma (Barnes et al. 1986). Interestingly, acute emotional stress may lead to activation of
mast cells in the bladder, an effect that is mediated by sensory nerves via the action of
sensory neuropeptides (Spanos et al. 1997). However, there is no evidence for efferent
pathways from the brain to the sensory nerves present in the coronary adventitia.
Therefore, other mechanisms have to be considered to explain the postulated mast cell
stimulation in the coronary adventitia during emotional stress. Intramyocardial mast cell
degranulation could be blocked by preincubation with antiserum against corticotropin-
releasing hormone (CRH), a potent mast cell secretagogue, and was partially inhibited by a
CRH type-1 receptor selective antagonist. Furthermore, the sensory neuropeptide
substance P did not appear to stimulate intramyocardial mast cells. (Huang et al. 2002).
Thus, it remains to be shown experimentally whether the mast cells of the human
epicardial coronary arteries are sensitive to the neuropeptides released from adjacent
sensory nerves or whether neurohumoral mechanisms, such as the CRH system, would be
responsible for the postulated stimulation of mast cells during acute mental stress.
6.2.3. Evidence for complement activation in advanced and ruptured plaques (III)
Various products of complement activation have been detected in atherosclerotic lesions
and the degree of complement activation has been shown to correlate with the severity of
the lesions (Vlaicu et al. 1985b, Torzewski et al. 1997). During complement activation,
complement factors, potent proinflammatory molecules and anaphylatoxins are generated.
These agents may then trigger the inflammatory response in the cells of the arterial wall.
Because of the apparent importance of complement activation in the development of
atherosclerotic lesions and the known ability of the complement components to activate
inflammatory cells, we studied (study III) the spatial relationship between complement
activation and inflammatory cell infiltration in advanced atherosclerotic lesions. Of the
complement components we analyzed deposition of iC3b and C5b-9. iC3b is generated
directly from C3b by two cleavages with factor I in the presence of a cofactor, usually
factor H derived from plasma, or the membrane cofactor protein (MCP, CD 46) or, on cell
membranes having the C3b receptor (CR1,CD 35; Morgan and Meri 1994).
In our study (Study III), extensive depositions of iC3b and C5b-9 were present in all the
atherosclerotic coronary plaques, this being most striking at the border between the intima
and the media. Importantly, strong positive staining for the iC3b and some weaker staining
for C5b-9 were also found at the actual rupture sites, suggesting, that complement
activation could be associated with inflammation leading to cap thinning and plaque
rupture.
How can activation of the complement cascade contribute to the weakening of the plaque,
which may ultimately lead to its rupture? During degradation of C3b to iC3b and C5 to
C5b-9, C3a and C5a are also generated. Activation of complement by cholesterol was
found to lead to a 30-fold greater cleavage of C3 than of C5 (Seifert et al. 1987). Although
C3a is generally considered to be a weak anaphylatoxin compared to C5a (Erdei et al.
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1997), it was recently shown that C3a can specifically activate monocytes/macrophages
(Rinder et al. 1999). Furthermore, the terminal complement complex C5b-9 may induce
expression of adhesion molecules on endothelial cells, activate various intimal cells to
secrete proatherogenic cytokines, and also potentially cause lysis of intimal cells (Morgan
et al. 1989, Hattori et al. 1989).
6.2.4. Expression of anaphylatoxin receptors in coronary mast cells (IV)
Complement activation, either by the antibody-dependent classical pathway or by the
alternative or lectin pathways, generates proinflammatory mediators such as
anaphylatoxins C3a and C5a. C3a can induce chemotaxis of mast cells (Hartmann et al.
1997), and trigger the release of mediators from mast cells (el-Lati et al. 1994). C3a can
also stimulate serotonin release from platelets (Fukuoka et al. 1988), and modulate
synthesis of IL-6 and TNF-α by monocytes (Fischer and Hugli 1997, Fischer et al. 1999).
C5a is chemotactic for monocytes (Arend et al. 1989), T cells (Nataf et al. 1999), and mast
cells (Schulman et al. 1988), and may cause migration of inflammatory cells into the
intima by upregulating the expression of adhesion molecules in endothelial cells (Foreman
et al. 1994). It also causes secretion of proinflammatory cytokines (Goodman et al. 1982,
Ember et al. 1994) and a respiratory burst in macrophages (Fischer et al. 1995), and causes
T cell proliferation (Morgan et al. 1983) and mast cell degranulation (Schulman et al.
1988, Marone et al. 1995).
Anaphylatoxins act on their target cells by binding to and activating highly ligand-specific
membrane receptors belonging to the family of seven transmembrane domain G-protein-
coupled receptors. The human C5a receptor (C5aR/CD88) was cloned in 1991, and has
been shown to be expressed both in myeloid cells and in various nonmyeloid cells (Hugli
et al. 2000). The human C3a receptor (C3aR) was cloned in 1996 and has been shown to
be expressed in blood neutrophils, monocytes, eosinophils, and basophils, but not in
circulating T or B lymphocytes (Martin et al. 1997, Zwirner et al. 1999b). Importantly, the
expression of both C5aR and C3aR is greatly increased during inflammation, as has been
demonstrated in the brain (Gasque et al. 1997, Gasque et al. 1998).
In study IV, the receptors for C3a and C5a were strongly expressed in atherosclerotic
lesions, but were absent from the normal intima. However, the cell types expressing these
receptors in the lesions differed. The receptor for C3a was abundantly expressed in
atherosclerotic lesions by macrophages, but not by other cell types. In contrast, C5aR was
found in all the types of inflammatory cell studied (macrophages, T lymphocytes, and mast
cells) and, in addition, in endothelial cells and in some smooth muscle cells. This is
consistent with a previous report showing the expression of C5aR in various myeloid and
non-myeloid cells (Zwirner et al. 1999a). The smooth muscle cells in the superficial
intima, but not those in the deep intima or in the media, were positive for C5aR, suggesting
that a phenotypic switch from contractile to matrix-synthesizing cells is required for
smooth muscle cells to be able to express C5aR.
These observations provide evidence that generation of C5a during complement activation
in advanced atherosclerotic coronary arteries could cause mast cell degranulation and by
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that means lead to the release of proteolytic enzymes, vasoactive compounds and TNF-α
from these cells . Furthermore, complement anaphylatoxins are known to be spasmogenic
to arteries (Vogt et al. 1986), but, consistent with our finding of the lack of anaphylatoxin
receptors in contractile smooth muscle cells, the spasmogenic effects of anaphylatoxins on
arteries may be indirect and, at least partly, mediated by mast cells, which upon stimulation
by C5a, release vasoactive compounds. Indeed, Ito et al. showed that intracoronary
administration of C5a into the left anterior descending coronary artery in pigs resulted in a
reduction of coronary blood flow and depression in regional myocardial contractile
function in the left anterior descending coronary region. This was accompanied by
increases in coronary venous thromboxane B2 and histamine, indicating mast cell
activation. Lodoxamide tromethamine, a mast cell inhibitor, reduced the C5a-induced
increase in coronary venous thromboxane B2 and histamine (Ito et al. 1993).
47
7. SUMMARY AND CONCLUSIONS
The general aim of this work was to elucidate the potential mechanisms which may
activate mast cells in human coronary arteries. The following immunohistochemical
observations were made in human atherosclerotic left anterior descending coronary arteries
(Figure 3).
I  In infarct-related LAD coronary arteries, the number of degranulated histamine-
containing mast cells, predominantly MCTC cells, in the adventitia backing the
ruptured plaques was found to be increased. Since many of the adventitial mast
cells were located adjacent to the adventitial vasa vasorum and at the border
between the adventitia and the media, the histamine released from the activated
mast cells may reach the media, where it may locally provoke coronary spasm and
so contribute to the onset of myocardial infarction.
II In the coronary adventitia, mast cells were found to connect with sensory nerve
fibers which contained neuropeptides capable of stimulating mast cells, i.e.
substance P (SP) and calcitonin gene-related peptide (CGRP). Neurogenic
stimulation of mast cells (MCTC) in the adventitia of atherosclerotic coronary
arteries may release vasoactive compounds, for example histamine, which can
contribute to abnormal coronary vasoconstriction and to the onset of acute coronary
syndromes.
III Evidence was found for complement activation in advanced coronary lesions,
especially at sites of plaque rupture. At these sites, there was strong staining for
iC3b and weaker staining for C5b-9, suggesting generation of other complement
activation products also, such as the anaphylatoxins C3a and C5a. Complement
activation in vulnerable areas of coronary plaques is a potential mechanism that
aggravates inflammation, which may contribute to plaque instability.
IV Finally, the expression of anaphylatoxin receptors (C3aR and C5aR) in coronary
mast cells and other inflammatory cells was studied. In addition, we searched for
evidence of C3d and C5b-9 as surrogate markers of the anaphylatoxins C3a and
C5a. In atherosclerotic coronary arteries, but not in nonatherosclerotic coronary
intimas, the two anaphylatoxin receptors and their respective ligands were present.
Plaque macrophages expressed both C3aR and C5aR, whereas plaque T cells and
mast cells expressed only C5aR. The presence of the molecular components
necessary for anaphylatoxin-mediated activation of inflammatory cells in coronary
plaques renders anaphylatoxin receptors potential candidates for the regulation of
vascular inflammation.
In summary, this work elucidated some of the potential mechanisms which may activate
mast cells in human coronary arteries. Two potential candidates for such mast cell
activation in human atherosclerotic coronary segments could be identified with the aid of
immunohistochemistry: (i) transmitters secreted by adventitial sensory nerves, and (ii)
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Future experimental work is necessary to confirm the importance of these two mechanisms
in mast cell activation, and ultimately to define the possible clinical significance of such
activation.
Figure 3. Schematic representation of an atherosclerotic coronary segment showing
the potential activation mechanisms of the coronary mast cells observed in this study.
SP = substance P, CGRP = calcitonin gene-related peptide, C5aR = C5a anaphylatoxin receptor,
C5b-9 = terminal complement C5b-9 proteins
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